Yicura BioMed eyes IPO as CEO says Hong Kong biotech scene needs more patient capital
Hong Kong needs more “patient capital” and more talent capable of commercialising research and development to sustain the city’s biotechnology ecosystem, according to a senior executive at a local biotech start-up. Yicura BioMed, based in the Hong Kong Science Park, is heading towards an initial public offering (IPO) in the city as soon as practicable, CEO Xian Jin said in…
Continue reading this story on South China Morning Post, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.